Registered title, quoted from ClinicalTrials.gov
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07528716, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Histologically confirmed unilateral primary invasive breast cancer, staged as at least cT2 or cN1 (i.e., AJCC 8th edition stage II-III), and M0.
Inclusion criterion 3
Pathologically confirmed HER2-positive breast cancer, defined as HER2 IHC 3+, or IHC 2+ with positive in situ hybridization (ISH).
Inclusion criterion 4
Women of childbearing potential must use at least one medically accepted contraceptive method during study treatment and for at least 3 months after the last dose of study drug.
Inclusion criterion 9
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Inclusion criterion 2
Biochemistry criteria: total bilirubin (TBIL) <= 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 x ULN; serum creatinine (Cr) <= 1.5 x ULN; endogenous creatinine clearance > 50 mL/min (Cockcroft-Gault formula).
Inclusion criterion 7
At least one measurable lesion according to RECIST version 1.1.
Inclusion criterion 5
Any other malignancy within the previous 5 years, except cured cervical carcinoma in situ or non-melanoma skin cancer.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07528716, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Female patients aged 18 to 75 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Histologically confirmed unilateral primary invasive breast cancer, staged as at least cT2 or cN1 (i.e., AJCC 8th edition stage II-III), and M0.
- Pathologically confirmed HER2-positive breast cancer, defined as HER2 IHC 3+, or IHC 2+ with positive in situ hybridization (ISH).
- At least one measurable lesion according to RECIST version 1.1.
- Adequate major organ function, meeting all of the following criteria: Hematology criteria (without blood transfusion or hematopoietic growth factor support within 7 days before screening): hemoglobin (HB) >= 90 g/L; absolute neutrophil count (ANC) >= 1.5 x 10\^9/L; platelet count (PLT) >= 75 x 10\^9/L.
- Biochemistry criteria: total bilirubin (TBIL) <= 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 x ULN; serum creatinine (Cr) <= 1.5 x ULN; endogenous creatinine clearance > 50 mL/min (Cockcroft-Gault formula).
- 12-lead electrocardiogram: Fridericia-corrected QT interval (QTcF) < 470 msec; echocardiography: left ventricular ejection fraction (LVEF) >= 55%.
- Women of childbearing potential must use at least one medically accepted contraceptive method during study treatment and for at least 3 months after the last dose of study drug.
- Subjects must voluntarily participate in the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up.
Exclusion Criteria:
- Bilateral breast cancer, inflammatory breast cancer, or clinically stage IV (metastatic) breast cancer.
- Any prior systemic targeted therapy, chemotherapy, endocrine therapy, biologic therapy, radiotherapy, or immunotherapy for any reason.
- Any of the following comorbidities, medical histories, or treatment histories:
- Known or suspected interstitial pneumonitis; or moderate to severe pulmonary disease severely affecting respiratory function, such as severe asthma or severe chronic obstructive pulmonary disease (COPD).
- Serious cardiovascular or cerebrovascular disease, including but not limited to New York Heart Association (NYHA) class II or higher heart failure (including class II), myocardial infarction or cerebrovascular accident (including cerebral ischemia or symptomatic cerebral infarction) within 3 months before first dosing, or persistent arrhythmia of grade >= 2.
- Severe systemic infection (e.g., requiring intravenous antibiotics, antifungal agents, or antiviral drugs according to clinical practice standards), or unexplained fever > 38.5 degrees C during screening or before first dosing.
- Clinically significant bleeding symptoms within 1 month before signing informed consent, or definite bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or baseline fecal occult blood of ++ or above.
- Known hypersensitivity or intolerance to the investigational medicinal products or their excipients.
- Any other malignancy within the previous 5 years, except cured cervical carcinoma in situ or non-melanoma skin cancer.
- Pregnancy or lactation, or refusal by women of childbearing potential to use appropriate contraception during the trial.
- Participation in another clinical trial within 30 days before the first dose of study drug.
- Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.
Quoted from ClinicalTrials.gov, NCT07528716, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07528716, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.